201 related articles for article (PubMed ID: 19483652)
1. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
3. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
4. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential.
Entwistle J; Brown JG; Chooniedass S; Cizeau J; MacDonald GC
Cancer Biother Radiopharm; 2012 Nov; 27(9):582-92. PubMed ID: 22856424
[TBL] [Abstract][Full Text] [Related]
6. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
[TBL] [Abstract][Full Text] [Related]
7. Bouganin, an Attractive Weapon for Immunotoxins.
Bortolotti M; Bolognesi A; Polito L
Toxins (Basel); 2018 Aug; 10(8):. PubMed ID: 30096764
[TBL] [Abstract][Full Text] [Related]
8. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
9. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
11. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
12. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
14. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Piselli P; Vendetti S; Poccia F; Cicconi R; Mattei M; Bolognesi A; Stirpe F; Colizzi V
J Biol Regul Homeost Agents; 1995; 9(2):55-62. PubMed ID: 9127634
[TBL] [Abstract][Full Text] [Related]
16. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody.
Wang Z; Zhang T; Hu H; Zhang H; Yang Z; Cui L; He W
Cancer Lett; 2008 Dec; 272(2):242-52. PubMed ID: 18782650
[TBL] [Abstract][Full Text] [Related]
17. A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo.
Luqiu Z; Yiquan K; Gengqiang L; Yijing L; Xiaodan J; Yingqian C
J Immunotoxicol; 2012; 9(4):353-8. PubMed ID: 22458328
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
Ek O; Waurzyniak B; Myers DE; Uckun FM
Clin Cancer Res; 1998 Jul; 4(7):1641-7. PubMed ID: 9676838
[TBL] [Abstract][Full Text] [Related]
20. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
